Pipeline
Addressing the most challenging tumors.
A multi-platform pipeline of first-in-class immunotherapies designed for the most intractable solid tumors.
Pipeline overview
Five programs, three platforms.
iOncologi’s multi-platform pipeline spans first-in-class immunotherapeutic approaches designed to address the most intractable solid tumors, including glioblastoma (GBM), non-small cell lung cancer (NSCLC) and EGFR-positive malignancies. Together, these programs leverage proprietary delivery technologies, precision immune activation, and AI-guided antigen discovery to re-engineer the tumor–immune interface.
A different approach.
Multi-modality innovation
Platforms span innate immune conditioning, off-the-shelf mRNA priming for checkpoint inhibitor therapy, and targeted tumor immunotherapy.
Breaking resistance
Specifically designed to overcome the immune suppression and checkpoint inhibitor resistance that define refractory tumors.
Rapid translation
Proprietary delivery systems enable efficient antigen presentation and potent immune priming without the need for extended patient-specific manufacturing in certain modalities.
Program highlights
Clinical and development progress.
IONC101 / IONC102
Multilamellar RNA nanocomplex
IONC101 is in Phase I clinical evaluation in adult and pediatric glioblastoma, with early translational data supporting activation of both innate and adaptive immune pathways and an acceptable safety profile. IONC102, built on the same platform with AI-optimized antigens, is in IND-enabling work.
Phase I ongoing in glioblastoma
IONC201 / IONC202
UNIFYR
Off-the-shelf mRNA paired with checkpoint inhibitors. IONC201 is planned for Phase II/III in NSCLC and other solid tumors; IONC202, using proprietary antigens, is in IND-enabling work in NSCLC.
Phase II/III planned
TAR001
Tumor-targeted nanoparticles
Targeting EGFR-positive solid tumors, supported by preclinical data showing potent tumor-specific immune activation and synergy with checkpoint inhibitors.
IND/CTA-ready; first-in-human planned
Let’s talk about what comes next.
Whether you partner or collaborate in research, the team would like to hear from you.